AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26450680 — intervention group
Group type: EXPERIMENTAL
Intervention: Late dinner group (dinner at 22:30 h)
Number of subjects: 14
Study 26450680 — intervention group
Group type: COMPARATOR
Intervention: Early dinner group (dinner at 17:30 h)
Number of subjects: 14
Study 26450680 — intervention group
Group type: EXPERIMENTAL
Intervention: Late dinner group
Number of subjects: 14
Study 26450680 — intervention group
Group type: COMPARATOR
Intervention: Early dinner group
Number of subjects: 14
Study 24252475 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided CBT self-help classes (Living Life to the Full - LLTTF), delivered over eight sessions.
Number of subjects: 0
Study 24252475 — intervention group
Group type: COMPARATOR
Intervention: Delayed access to guided CBT self-help classes (Living Life to the Full - LLTTF), delivered over eight sessions.
Number of subjects: 0
Study 21328472 — intervention group
Group type: EXPERIMENTAL
Intervention: Brindley stimulator
Number of subjects: 93
Study 21328472 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 93
Study 19641042 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by concurrent chemoradiation in SCCHN patients (TAX 324 trial)
Number of subjects: 106
Study 19641042 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-positive oropharyngeal cancer patients
Number of subjects: 106
Study 19641042 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV status assessment
Number of subjects: 106
Study 19641042 — intervention group
Group type: COMPARATOR
Intervention: Non-oropharyngeal SCCHN patients
Number of subjects: 106
Study 19641042 — intervention group
Group type: COMPARATOR
Intervention: HPV-negative patients
Number of subjects: 106
Study 17605495 — intervention group
Group type: EXPERIMENTAL
Intervention: RMCC appliance
Number of subjects: 30
Study 17605495 — intervention group
Group type: EXPERIMENTAL
Intervention: Class II elastics on UAs
Number of subjects: 30
Study 17605495 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated persons)
Number of subjects: 30
Study 15486384 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-body strength training
Number of subjects: 67
Study 15486384 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 67
Study 15486384 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 67
Study 11564014 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock waves focused on the end of the contrast medium column (Group 1)
Number of subjects: 156
Study 11564014 — intervention group
Group type: COMPARATOR
Intervention: Shock waves focused 5 mm beyond the end of the contrast medium column (Group 2)
Number of subjects: 156
Study 9783350 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/day sertraline
Number of subjects: 40
Study 9783350 — intervention group
Group type: COMPARATOR
Intervention: 150 mg/day imipramine
Number of subjects: 40
Study 7838913 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 24
Study 7838913 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (25 mg)
Number of subjects: 24
Study 7838913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3279969 — intervention group
Group type: EXPERIMENTAL
Intervention: Complamin (1 g t.i.d.)
Number of subjects: 0
Study 3279969 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine (4 g b.i.d.)
Number of subjects: 0
Study 3279969 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Complamin and cholestyramine
Number of subjects: 0
Study 31232638 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat stimuli at -5 dB SNR
Number of subjects: 13
Study 31232638 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat and staircase stimuli in all SNRs
Number of subjects: 13
Study 31232638 — intervention group
Group type: EXPERIMENTAL
Intervention: P1 and N1 latencies due to noisy CAEPs
Number of subjects: 13
Study 28395845 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary feeding at 4 months corrected age
Number of subjects: 403
Study 28395845 — intervention group
Group type: COMPARATOR
Intervention: Complementary feeding at 6 months corrected age
Number of subjects: 403
Study 28395845 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital admissions
Number of subjects: 403
Study 25735313 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training with Tilt Sensor FES (TTSF)
Number of subjects: 30
Study 25735313 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training with Placebo Tilt Sensor FES (TPTSF)
Number of subjects: 30
Study 23587943 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate plus sulfadoxine-pyrimethamine (AS+SP) with primaquine (0.75 mg/kg) on day 2
Number of subjects: 1335
Study 23587943 — intervention group
Group type: COMPARATOR
Intervention: Artesunate plus sulfadoxine-pyrimethamine (AS+SP) alone
Number of subjects: 1335
Study 21512491 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of IRS 19
Number of subjects: 0
Study 21512491 — intervention group
Group type: COMPARATOR
Intervention: Irrigation of the nasopharynx with saline solutions
Number of subjects: 0
Study 19146567 — intervention group
Group type: EXPERIMENTAL
Intervention: TRIP intervention
Number of subjects: 12
Study 17002812 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral lower limb suspension (ULLS) for 20 days
Number of subjects: 8
Study 15177863 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin care
Number of subjects: 28
Study 15177863 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 28
Study 11672942 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral flupenthixol (2.5 or 5.0 mg; p.o.)
Number of subjects: 23
Study 11672942 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular flupenthixol decanoate (10 or 20 mg; i.m.)
Number of subjects: 23
Study 11672942 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose flupenthixol
Number of subjects: 23
Study 11672942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 9389840 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (maximum inspired concentration 8%)
Number of subjects: 100
Study 9389840 — intervention group
Group type: COMPARATOR
Intervention: Halothane (maximum inspired concentration 5%)
Number of subjects: 100
Study 8179047 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted work-site smoking policy
Number of subjects: 67
Study 3034040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (2.5 to 10 mg daily) - once-daily administration
Number of subjects: 39
Study 3034040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (2.5 to 10 mg daily) - twice-daily administration
Number of subjects: 39
Study 3034040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (2.5 to 10 mg daily)
Number of subjects: 39
Study 29354931 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 120
Study 29354931 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulligan's mobilization
Number of subjects: 120
Study 29354931 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (EA + Mulligan's mobilization)
Number of subjects: 120
Study 27319970 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT‐126 50 mg
Number of subjects: 432
Study 27319970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 432
Study 26280376 — intervention group
Group type: EXPERIMENTAL
Intervention: Expand Your Horizon programme
Number of subjects: 81
Study 26280376 — intervention group
Group type: COMPARATOR
Intervention: Active control programme
Number of subjects: 81
Study 23660378 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 g AA kg(‐1) · d(‐1) plus 2‐3 g lipids kg(‐1) · d(‐1) (AA + lipid group)
Number of subjects: 144
Study 23660378 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 g AA kg(‐1) · d(‐1) plus 2‐3 g lipids kg(‐1) · d(‐1) (high AA + lipid group)
Number of subjects: 144
Study 23660378 — intervention group
Group type: COMPARATOR
Intervention: 2.4 g AA kg(‐1) · d(‐1) (control group)
Number of subjects: 144
Study 21908683 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolic protection device
Number of subjects: 100
Study 21908683 — intervention group
Group type: COMPARATOR
Intervention: Platelet glycoprotein IIb/IIIa inhibitor
Number of subjects: 100
Study 21908683 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with abciximab and Angioguard(®) embolic protection
Number of subjects: 100
Study 18162662 — intervention group
Group type: EXPERIMENTAL
Intervention: Female-relevant content domain
Number of subjects: 0
Study 18162662 — intervention group
Group type: EXPERIMENTAL
Intervention: Male-relevant content domain
Number of subjects: 0
Study 18162662 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational manipulations
Number of subjects: 0
Study 16787523 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system (CGMS)
Number of subjects: 27
Study 16787523 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 27
Study 16787523 — intervention group
Group type: EXPERIMENTAL
Intervention: CGMS
Number of subjects: 27
Study 14711164 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report measures of condom use
Number of subjects: 0
Study 11471077 — intervention group
Group type: EXPERIMENTAL
Intervention: TRA1 (Trachoma Rapid Assessment 1)
Number of subjects: 13
Study 11471077 — intervention group
Group type: EXPERIMENTAL
Intervention: TRA2 (Trachoma Rapid Assessment 2)
Number of subjects: 13
Study 11471077 — intervention group
Group type: COMPARATOR
Intervention: Door-to-door survey
Number of subjects: 13
Study 9551726 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal smoking cessation advice from a respiratory physician with person-specific health advice and a pamphlet on smoking cessation, n=1,300
Number of subjects: 2610
Study 9551726 — intervention group
Group type: COMPARATOR
Intervention: Control group with no information, n=1,310
Number of subjects: 2610
Study 9551726 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal smoking cessation advice from a respiratory physician, n=1,300
Number of subjects: 2610
Study 7999812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal antibiotics (Cephalothin, cefazolin, vancomycin, ceftazidime, aminoglycosides tobramycin and gentamicin)
Number of subjects: 1930
Study 7999812 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglycosides alone
Number of subjects: 1930
Study 7999812 — intervention group
Group type: EXPERIMENTAL
Intervention: Single drug therapy
Number of subjects: 1930
Study 7999812 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial intraperitoneal therapy for both gram-positive and gram-negative bacteria
Number of subjects: 1930
Study 3057482 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene (DXP) 130 mg
Number of subjects: 15
Study 3057482 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene (DXP) 65 mg + Amitriptyline (AMI) 25 mg
Number of subjects: 15
Study 3057482 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (IN) 50 mg
Number of subjects: 15
Study 3057482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31757517 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fatal overdose (NFOD) incidence after release from prison
Number of subjects: 1307
Study 31757517 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent history of substance use disorder (SUD)
Number of subjects: 1307
Study 31757517 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual diagnosis of mental illness and SUD
Number of subjects: 1307
Study 31757517 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime history of injecting drug use
Number of subjects: 1307
Study 31757517 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime history of NFOD
Number of subjects: 1307
Study 31757517 — intervention group
Group type: EXPERIMENTAL
Intervention: Being dispensed benzodiazepines after release
Number of subjects: 1307
Study 31757517 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter index incarceration
Number of subjects: 1307
Study 31757517 — intervention group
Group type: EXPERIMENTAL
Intervention: Low perceived social support
Number of subjects: 1307
Study 31757517 — intervention group
Group type: COMPARATOR
Intervention: High-risk alcohol use
Number of subjects: 1307
Study 31757517 — intervention group
Group type: COMPARATOR
Intervention: While incarcerated
Number of subjects: 1307
Study 29872112 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic sleep deprivation (SD) for 36 hours
Number of subjects: 93
Study 29872112 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic sleep deprivation (SD)
Number of subjects: 93
Study 27989008 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 46
Study 27989008 — intervention group
Group type: COMPARATOR
Intervention: Local Anesthetic (LA)/Corticosteroid
Number of subjects: 46
Study 26559317 — intervention group
Group type: EXPERIMENTAL
Intervention: Andexanet bolus for apixaban (24 participants)
Number of subjects: 74
Study 26559317 — intervention group
Group type: COMPARATOR
Intervention: Placebo for apixaban (9 participants)
Number of subjects: 74
Study 26559317 — intervention group
Group type: EXPERIMENTAL
Intervention: Andexanet bolus for rivaroxaban (27 participants)
Number of subjects: 74
Study 26559317 — intervention group
Group type: COMPARATOR
Intervention: Placebo for rivaroxaban (14 participants)
Number of subjects: 74
Study 24285938 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg/day for 8 weeks
Number of subjects: 60
Study 24285938 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 50 mg/day for 8 weeks
Number of subjects: 60
Study 20833759 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management intervention (SMI)
Number of subjects: 174
Study 20833759 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 174
Study 18344636 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal tulobuterol patch (TP)
Number of subjects: 16
Study 18344636 — intervention group
Group type: COMPARATOR
Intervention: Slow-release theophylline
Number of subjects: 16
Study 16864110 — intervention group
Group type: EXPERIMENTAL
Intervention: Deoxyribonucleotidum injection
Number of subjects: 80
Study 12704355 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 30 mg (n = 464)
Number of subjects: 935
Study 12704355 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 471)
Number of subjects: 935
Study 10634340 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 40
Study 10634340 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with supplemental oxygen
Number of subjects: 40
Study 9385125 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone (200 microg twice daily)
Number of subjects: 241
Study 9385125 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg twice daily)
Number of subjects: 241
Study 9385125 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 241
Study 9385125 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone
Number of subjects: 241
Study 9385125 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 241
Study 1348061 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg, four times daily for 3 weeks
Number of subjects: 17
Study 1348061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 1348061 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 17
Study 30412281 — intervention group
Group type: EXPERIMENTAL
Intervention: S5 methylation testing
Number of subjects: 257
Study 30412281 — intervention group
Group type: COMPARATOR
Intervention: Combined abnormal cytology/HPV16/18 positivity
Number of subjects: 257
Study 30605935 — intervention group
Group type: EXPERIMENTAL
Intervention: JOAG patients
Number of subjects: 25
Study 30605935 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 25
Study 27457255 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose implant
Number of subjects: 36
Study 27457255 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose implant
Number of subjects: 36
Study 27457255 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 36
Study 27457255 — intervention group
Group type: EXPERIMENTAL
Intervention: Explanted eyes
Number of subjects: 36
Study 24495042 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab with grade 2+ rash
Number of subjects: 0
Study 24495042 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab with grade 0/1 rash
Number of subjects: 0
Study 24495042 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab with KRAS mutated tumours (any rash grade)
Number of subjects: 0
Study 24495042 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study 22999098 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy (KIN)
Number of subjects: 40
Study 22999098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 40
Study 22999098 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 40
Study 20179212 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab 6 mg/kg every 2 weeks
Number of subjects: 68
Study 20179212 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab 9 mg/kg every 3 weeks
Number of subjects: 68
Study 17296972 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 611
Study 17296972 — intervention group
Group type: COMPARATOR
Intervention: MBS
Number of subjects: 611
Study 16224086 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment group from phase III ischemic stroke therapy trials
Number of subjects: 6
Study 12392866 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight mail delivery
Number of subjects: 664
Study 12392866 — intervention group
Group type: EXPERIMENTAL
Intervention: No certificate of appreciation
Number of subjects: 664
Study 12392866 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of administration close to study closeout
Number of subjects: 664
Study 12392866 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey distribution methods
Number of subjects: 664
Study 12392866 — intervention group
Group type: EXPERIMENTAL
Intervention: Respondents characteristics
Number of subjects: 664
Study 12392866 — intervention group
Group type: COMPARATOR
Intervention: Nonrespondents characteristics
Number of subjects: 664
Study 9920089 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human FSH (r-hFSH)
Number of subjects: 24
Study 9920089 — intervention group
Group type: EXPERIMENTAL
Intervention: low dose recombinant human LH (r-hLH) (150 IU, twice daily)
Number of subjects: 24
Study 9920089 — intervention group
Group type: EXPERIMENTAL
Intervention: high dose recombinant human LH (r-hLH) (375 IU, twice daily)
Number of subjects: 24
Study 9920089 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 24
Study 7661074 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral anticoagulant and antiplatelet therapy
Number of subjects: 5
Study 2292620 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally sensitive modeling therapy
Number of subjects: 0
Study 2292620 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 7024156 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin (10 mg nocte)
Number of subjects: 45
Study 7024156 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 45
Study 7024156 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin
Number of subjects: 45
Study 7024156 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin and placebo
Number of subjects: 45
Study 31176788 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 ppm fluoridated dentifrice
Number of subjects: 345
Study 31176788 — intervention group
Group type: COMPARATOR
Intervention: 1,450 ppm fluoridated dentifrice
Number of subjects: 345
Study 28091349 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 68
Study 28091349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 25951907 — intervention group
Group type: EXPERIMENTAL
Intervention: Team Awareness (TA) intervention, 8 hours duration
Number of subjects: 325
Study 25951907 — intervention group
Group type: COMPARATOR
Intervention: One-hour wellness talk (Control)
Number of subjects: 325
Study 24188573 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level intervention to reduce antibiotic prescribing
Number of subjects: 29
Study 24188573 — intervention group
Group type: EXPERIMENTAL
Intervention: Exam room poster depicting a diagnostic algorithm
Number of subjects: 29
Study 24188573 — intervention group
Group type: EXPERIMENTAL
Intervention: General intervention strategies
Number of subjects: 29
Study 21127308 — intervention group
Group type: EXPERIMENTAL
Intervention: Etilefrine
Number of subjects: 131
Study 21127308 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 131
Study 21127308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 19167961 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate group intervention (n=55)
Number of subjects: 103
Study 19167961 — intervention group
Group type: COMPARATOR
Intervention: Delayed group intervention (n=48)
Number of subjects: 103
Study 17377238 — intervention group
Group type: EXPERIMENTAL
Intervention: LapSim System (virtual reality laparoscopic simulator)
Number of subjects: 2
Study 17377238 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 2
Study 15497908 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone (1, 2 or 3 mg) combined with estradiol (1 mg)
Number of subjects: 0
Study 15497908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11150476 — intervention group
Group type: EXPERIMENTAL
Intervention: Early blind subjects
Number of subjects: 5
Study 11150476 — intervention group
Group type: COMPARATOR
Intervention: Sighted control subjects
Number of subjects: 5
Study 9130150 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder protraction measurement
Number of subjects: 55